Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Aumolertinib Combined With Phased Chemotherapy for Treatment-Naïve EGFR L858R-Mutated Lung Adenocarcinoma (ACCEL Trial)

NCT07624487 is registered in ClinicalTrials.gov with Taipei Medical University Hospital as lead sponsor.

NCT NCT07624487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07624487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Aumolertinib Combined With Phased Chemotherapy for Treatment-Naïve EGFR L858R-Mutated Lung Adenocarcinoma (ACCEL Trial)
Lead sponsor
Taipei Medical University Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
June 9, 2026
Completion date
December 31, 2028
Enrollment
50 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

lung adenocarcinoma metastatic